SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-024532
Filing Date
2023-07-14
Accepted
2023-07-14 06:03:15
Documents
13
Period of Report
2023-07-13
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 39356
2 ex10-1.htm EX-10.1 28557
  Complete submission text file 0001493152-23-024532.txt   243680

Data Files

Seq Description Document Type Size
3 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ocx-20230713.xsd EX-101.SCH 3012
4 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ocx-20230713_lab.xml EX-101.LAB 34240
5 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ocx-20230713_pre.xml EX-101.PRE 22358
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3185
Mailing Address 15 CUSHING IRVINE CA 92618
Business Address 15 CUSHING IRVINE CA 92618 949-409-7600
Oncocyte Corp (Filer) CIK: 0001642380 (see all company filings)

IRS No.: 271041563 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37648 | Film No.: 231087979
SIC: 2835 In Vitro & In Vivo Diagnostic Substances